Pruritus is a common presenting diagnosis associated with a myriad of localized and systemic conditions. Due to many underlying causes, it can be challenging for the provider to assess. Symptoms often persist, causing frustration for the patient and provider, as well as distress and impaired quality of life for the patient. When evaluating patients with neurodermatitis or pruritus in the absence of primary skin lesions, a full workup assessing for medication-induced disease and underlying systemic conditions is warranted. Treatment of the underlying cause, if found, is always recommended. For all patients, interventions such as moisturizing, avoidance of irritating agents, avoidance of heat, and stress reduction should be considered. Further management of symptoms can include topical, systemic agents or non-pharmacologic therapies such as phototherapy, transcutaneous and transcranial nerve stimulation, acupuncture, and psychosomatic therapy. This review focuses on the pathophysiology, evaluation, and management of the patient with neurodermatitis. It will also provide a discussion of traditional and emerging therapies to help formulate diagnostic and treatment paradigms for these patients.
Introduction
Neurodermatitis is defined as pruritus in the absence of primary skin findings [1] . Primary skin findings are lesions not manipulated by the patient and represent a primary or endogenous process as opposed to excoriated lesions (secondary lesions) [2] . The condition begins with an itch, and may or may not manifest skin changes as it progresses. Scratching the itch generally does not relieve the itch, and it often progresses to a chronic condition marked by an itchscratch-itch cycle that can be difficult to break. Subsequently, inflammatory skin changes caused by chronic itching often present in the affected area [3] . Symptoms can be significant and distressing, causing impaired quality of life for the patient, as well as frustration for the provider [4] . Causative mechanisms of neurodermatitis can often be complex, and generating an appropriate broad and relevant differential diagnosis is essential. This condition can represent local or underlying systemic disease, and a meticulous review of systems must be performed [5] .
Successful treatment of neurodermatitis requires disruption of the itch-scratch-itch cycle. Pharmacological and nonpharmacological therapies are available, as well as diseasespecific therapies [3, 5] . In addition, many emerging treatments for pruritus can be used in accordance with this clinical presentation, and are associated with variable degrees of evidence-based research support. This review of neurodermatitis summarizes published data on the treatments available for patients with pruritus in the absence of skin findings. We will discuss general pathophysiology, differential diagnosis, evaluation, and management. Review-based algorithms for evaluation and management will also be provided.
Pathophysiology
Pruritus can be categorized into neurogenic, neuropathic, pruritoceptive, and psychosomatic types (Table 1) ( Fig. 1 ) [5] . Neurodermatitis specifically encompasses neurogenic, neuropathic, and psychogenic etiologies, as these types present without primary skin findings.
Neurogenic Itch
Neurogenic itch is a centrally mediated itch without neural damage that affects organ systems other than the skin and is associated with a variety of systemic causes such as renal, hepatic, and hematologic diseases; malignancy; and medications [6] . Although the exact mechanisms are currently unknown, opioids are thought to play a role, as it is hypothesized that this centrally induced itch is associated with increased accumulation of endogenous or exogenously administered opioids [3, 5, 7] . Supporting evidence for this includes that itch is a well-known side effect of opiate medications, and secondly, opioid receptor antagonists (naltrexone) have antipruritic effects for patients with systemic disease [7, 8] . Another mediator thought to be important is serotonin [9] . Support for this comes from the use of serotonin antagonists (SSRIs) in treating pruritus from systemic conditions [10] .
Neuropathic Itch
Neuropathic itch stems from either a central lesion or a lesioned area anywhere along the afferent nerve. A proposed mechanism of neuropathic itch involves damage to the nerve, loss of afferent input centrally, and central hypersensitivity of nerve fibers [11] . In neuropathic pruritus, dermatomes of itch-mediating nerve fibers in the skin are activated. These fibers converge to C-fibers, both histamine-dependent and histamine-independent (cowhage) pathways of small unmyelinated fibers that transmit itch and pain. These C-fibers synapse in the gray matter of the dorsal horn before crossing over and ascending in the lateral spinothalamic tract to the thalamus. Because these fibers transmit both pain and itch, it is believed that painful stimuli can reduce the sensation of itch through an inhibitory interneuron (Bhlhb5) located in the dorsal horn of the spinal cord ( Fig. 2) [11] . The end result is that processing of itch through either pathway (histamine or cowhage) activates several regions of the brain, similar to those involved in pain. Many mediators are thought to play a role in neuropathic itch (Supplemental Table 1 ).
The distinct characteristic of neuropathic itch is that because C-fibers transmit other sensations such as pain, this itch is often accompanied by other neurologic symptoms like pain, paresthesia, and hyper-or hypoesthesia. Since the lesion of the affected nerve is often away from the itchy area, scratching the itch is often ineffective, and patients can self-inflict additional lesions by repetitive scratching [6] .
Psychosomatic Itch
Psychogenic itch is related to psychiatric disorders such as anxiety, depression, delusional disorders, and obsessivecompulsive disorder. Although clinical trials for this subset of disease are lacking, dermatologists and psychiatrists have described an association between psychiatric disease and itch. However, there is no clear definition of this entity in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). The pathophysiology of this subset of pruritus is currently unknown and is typically considered a diagnosis of exclusion. Histamine (epidermis) and cowhage (dermis) as well as pain pathways are shown. Nociceptors located at the free nerve endings of these unmyelinated C-fibers can be activated by noxious thermal, chemical, or mechanical stimuli. Pain modulates itch by activating Bhlbb5 interneuron, which then inhibits both the histamine and cowhage itch pathways.
GPCRs G-protein coupled receptors, TRPV1 transient receptor potential cation channel receptor, TRPA1 transient receptor potential cation channel receptor, PAR2 protease-activated receptor, GRP gastrin releasing peptide, Glu glutamate, SP substance P, BNP brain-derived natriuretic peptide, CMi mechano-insensitive fibers 
Clinical Presentation
Patients with neurodermatitis typically present with a history of excessive itch which may be generalized or localized. They may report that certain activities aggravate their symptoms, such as stress, heat, sweat, or contact with irritants. In many instances, however, patients often cannot identify a specific trigger. On examination, nonspecific secondary skin changes may be seen (e.g., excoriations, erosions, skin thickening, accentuation of skin lines), or patients may present with no skin findings.
Evaluation of the Patient with Itch
When there are minimal skin findings or no primary lesions in pruritic patients, identification of its etiology can be challenging and some entities can be overlooked. As pruritus can be a sign of underlying systemic disease, the first step is to determine whether or not the pruritus is secondary to a localized or generalized disease. A comprehensive assessment, including detailed history, review of systems, and complete physical exam, is recommended. Potential causes of neurodermatitis can be categorized as metabolic, hematologic, neoplastic, infectious, central nervous system related, pregnancy related, psychogenic, or medication induced (Table 2) . Additionally, the following may help during evaluation [3, 10, 12, 13] :
& Acute onset of pruritus without primary skin lesions over several days is less suggestive of an underlying systemic disease than chronic, progressive, generalized pruritus. & Lesions on the mid upper back suggest a primary skin disease since this region is usually spared from direct scratching. & Medications (prescription, over-the-counter, and illicit) and supplements the patient is taking should be reviewed for drug-induced causes. & Severely pruritic dermatoses like urticaria and mastocytosis uncommonly lead to excoriations from scratching. Instead, they present with pressing and rubbing behaviors. & Scabies and other infestations should be considered especially when family members are affected. In the setting of pruritus without a known cause, laboratory evaluation is recommended. General and patient-specific laboratory studies to consider can be found in Table 3 . Imaging studies, like a chest x-ray, may be useful if clinically warranted. In addition, age appropriate cancer screening is recommended. If primary lesions are suspected, consider referring to a dermatologist for evaluation.
Treatment
Treatment of the underlying cause, if found, is essential. As workup for an underlying cause can take weeks to months, symptomatic treatment while evaluation proceeds may be warranted. Counseling by the physician and frequent followups are helpful to establish trust.
For all patients, non-pharmacologic interventions like moisturizing, avoidance of irritants, and stress reduction should be recommended. Treatment options available include topical and systemic agents (Table 4 ). Typically, topical agents are best when there is localized pruritus, while systemic agents are preferred in the presence of generalized disease. As initial treatment, the physician may consider capsaicin cream, topical corticosteroids, topical anesthetics such a lidocaine, pramoxine or EMLA, and/or oral antihistamines. If unsuccessful, gabapentin, pregabalin, doxepin, amitriptyline, or paroxetine may be utilized.
There are several emerging therapies for patients with unsatisfactory response to treatment. Substance P and neurokinin-1 (NK-1) are involved in the neurotransmission of pruritus and selective antagonism of their activity may decrease symptoms. An example of this is the use of aprepitant for patients with mycosis fungoides and serlopitant for patients with recalcitrant itch [14] [15] [16] . Thalidomide has shown success in decreasing symptoms of itch from refractory paraneoplastic pruritus, cholestasis, uremia, and mycosis fungoides through inhibition of tissue necrosis factor alpha [17] . Since opioid receptors have been shown to modulate pruritus, μ and κ receptor antagonism with the use of naltrexone or naloxone can decrease itch perception [18] . Topical cannabinoid receptor agonists have shown success in decreasing pruritic sensation [19] .
Azathioprine has been successful in patients with steroidresponsive intractable pruritus. However, 33% of patients had side effects severe enough to warrant premature cessation of the drug in one study [20] . Emergent therapies for itch include the anti-interleukin-31 receptor A antibody nemolizumab, which has been shown to decrease pruritus in patients with atopic dermatitis [21] [22] [23] [24] [25] , and topical N-methyl-D-aspartate (NMDA) antagonists such as ketamine. When topical NMDA is used in conjunction with amitriptyline, it can greatly reduce chronic pruritus [26, 27] . Another emerging therapy is stellate ganglion blocks with bupivacaine [28] . Other therapies to consider when treating with pruritus include nonpharmacologic interventions like phototherapy, transcutaneous and transcranial nerve stimulation, acupuncture, and psychosomatic therapy. However, evidence for these therapies is limited [29] [30] [31] .
Conclusions
Evaluation of neurodermatitis includes a full workup to assess for drug causes or the presence of underlying systemic disease. Treatment of the underlying cause, if found, is always recommended. Symptomatic treatment while an evaluation proceeds is essential. This can include topical, systemic agents or non-pharmacologic therapies. To best help patients, physicians should be familiar with advantages and disadvantages of each therapy.
